Atracurium and vecuronium are reviewed with reference to the following aspects:
were to develop a bis-quaternary competitive neuromuscular blocker, highly selective in its action which would degrade to inactive metabolites without renal or hepatic intervention. A chemical structure liable to degradation along the Hofmann elimination pathway was chosen. The process which eventually led to atracurium is described by Stenlake. 2 Considerations of solubility and stability led to the choice of the besylate salt for marketing as a solution containing 25 mg of the drug in 2.5 ml of aqueous solution at pH 3.5 which has a shelf life of at least two years. The atracurium molecule has four centres of asymmetry and therefore sixteen isomers are possible but because of molecular symmetry, they reduce to ten. The RR, SS and RS compounds can be separated by magnetic resonance techniques while the geometrical isomers, CIS-CIS, TRANS-TRANS and TRANS-CIS can be separated by high performance liquid chromatography. ) The story of vecuronium is somewhat different. 4 It is the monoquaternary analogue of pancuronium and was first synthesised more than twenty years ago by Savage and coworkers at the Organon Research Laboratories, in the same series of androstane compounds which yielded pancuronium. It is said that at that time pancuronium was one of the first of the drugs in the synthesised series to be tested in vivo. Obviously it proved an excellent drug and interest in the other members of the series waned. When its monoquaternary analogue was tested, its potency was found to be low, possibly due to instability in storage. It was therefore not subjected to further attention. Nonetheless, when interest in a 'cleaner' (i.e. more selective) and shorter-acting competitive neuromuscular blocker was revived, reexamination of the series brought Org NC 45 to attention once more.
Vecuronium is a white powder which is soluble but unstable in aqueous solutions over a wide range of pH, the acetate groups at 3 and 17 being liable to hydrolysis. It is therefore packaged as a lyophyllised product, in citratephosphate buffer which dissolves on addition of I ml water to pH of 4. Each ampoule contains 4 mg of the drug, 8.3 mg citric acid, 6.5 mg disodium phosphate and 24.5 mg mannitol to make it isotonic. Sodium hydroxide or phosphoric acid may be added to adjust the pH. The phosphate not only serves as buffer, but also binds any trace of water left during ampouling. When stored in daylight, after reconstitution to 1 ml, decomposition is only 1-2070 after 24 hours at 25 QC. There appears to be no reason why two ampoules of the substance should not be reconstituted with 4 ml of water or saline immediately before use, to yield the same concentration (2 mg/ml) as pancuronium thus retaining familiar drug volumes for administration. Dilutions of 40 to 100 mg/l in normal saline, 5070 glucose, Hartmann's solution or Ringer's-glucose solution, suitable for infusion, have been tested and found stable for 24 hours at room temperature. 4 
PHARMACOLOGY
Both drugs are competitive acetylcholine antagonists at the NMJ, with some apparent prejunctional actions as evidenced by tetanic fade and train of four ratio decrement. Work in progress in the writer's department at present suggests that both these effects are more marked with vecuronium than with atracurium.
Potency and dosage
Two methods are commonly used to construct dose-response curves for relaxant drugs. The traditional method of administering a bolus dose, measuring the effect and constructing the (log) dose-response curve by POlency dala for alracurium and vecuronium. Where anaeslhesia is indicaled as IV Ihe sludy was done wilh Ihiopenlone, fenlanyl, nilrous oxide anaeslhesia. In Ihe 'Melhod' column, '5' determining the line of best fit requires large numbers of patients. The alternative, 'cumulative' method consists of administering a small dose, the resulting twitch depression is observed and as soon as maximal effect is noted, additional doses are given. Thus each experimental subject contributes several points to the data from which the dose-response relation is derived. When applied to longer acting neuromuscular blockers, the two methods gave similar results.s For vecuronium and atracurium, however, the difference between the two methods is significant and the cumulative method yields larger values for ED90, probably because the effect of the early doses has dissipated before the last dose is given. This accounts for some of the variability in the reported values for the potency of these drugs. Under nitrous oxide-oxygen anaesthesia supplemented with intravenous agents, the reported ED90 or ED95 ranges from 44 to 56 /-Ig/kg for vecuronium 6 ,7 and from 200 to 279 /-Ig/kg for atracurium 7 ,8 when used without potent inhalation agents. Table 1 shows the range of values reported in the literature for the potencies of the two drugs. Although the potencies of the atracuri urn isomers vary, 3 the mixture behaves like a single drug. 9 Further variability is introduced if potent volatile agents are used. The potency of vecuronium thus appears to be slightly (l 0-20070) greater than that of pancuronium, while that of atracurium is in turn somewhat greater than that of d-tubocurarine.
The usual clinical dose of atracurium varies from 300 to 600 /-Ig/kg and that of vecuronium from 80 to 100 /-Ig/kg. These doses result in complete twitch suppression for 20 to 30 minutes. Subsequent doses are usually one-fifth to one-third of the initial dose. Both drugs are suitable for use by administration of a bolus dose for intubation, followed by an infusion for maintenance of relaxation. For vecuronium, a loading dose of 75 /-Ig/kg followed by 75 /-Ig/kg/hr is a reasonable scheme lO although some may prefer a larger dose, say lOO /-Ig/kg for intubation. For atracurium a loading dose of 600 /-Ig/kg followed by 200 to 500 /-Ig/kg/hr has been reported. 11 For complete immobility, considerably higher infusion rates may need to be used, such as I mg/kg/hr (D. A. Pybus, Anaesthesia and flllet/siv!! Care. Vol. 15, ,Vo. /, February, /987 personal communication). In the writer's experience there is a wide range of individual variation, and therefore infusions are best used in conjunction with continuous monitoring of neuromuscular transmission. Recovery rates are similar to those following bolus doses.
Onset and duration
Using small experimental doses, which do not abolish the twitch, time to maximum effect for atracurium was from 4.2 to 8 min in a sample of 10 patients. For vecuronium it was not significantly different (unpublished data). When larger clinical doses which suppress the twitch completely are used, the time appears shorter. With a dose four times ED95 vecuronium had an onset time of 1.3 min 12 and atracurium, at three ED95 was similar. 13 Neither drug is as rapid in onset as suxamethonium 14 and using equipotent doses no difference in onset time could be found between the two drugs. IS The duration of action of these two drugs is remarkably similar and about one-third to onehalf that of pancuronium. The initial doses suggested above tend to give good clinical relaxation for 25 to 40 minutes. Incremental doses of one-fifth to one-third of the initial dose result in good relaxation for 10 to 20 minutes. In practical terms, the suggested clinical doses give adequate intubating conditions in most patients within two minutes or so. Most experienced users agree that suxamethonium generally remains the drug of choice for rapid sequence intubation. Recovery time (25070 to 75070) is reported between 10 and 14 minutes for both drugs. 7 . 8 • 16 Cumulative effects are generally not reported 17 or slight. 16 
Non-neuromuscular effects, Cardiovascular effects
Drugs which compete with acetylcholine for receptors at the NMJ (N2 receptors) are also likely to compete at other cholinergic sites, such as the muscarinic receptors and the nicotinic receptors at ganglia (NI). Part of the search for new relaxants was for drugs highly specific to the NMJ in their action. The degree of specificity can be expressed as a ratio of the ED 50 at one site to that at another. The most commonly used model is that of Hughes and Chapple l8 which compares the dose necessary to block neuromuscular transmission to that necessary to prevent bradycardia and hypotension on stimulation of the vagus (muscarinic receptor block) and that required to prevent contraction of the nictitating membrane on pre-ganglionic stimulation of the cervical ganglion (ganglionic block) in the anaesthetised cat. On this type of preparation vecuronium was about 80 times as potent at the NMJ than at the vagus, and ganglion blockade (N 1 block) was not detected at clinically relevant dosage.1 9 ,20 Neither does vecuronium appear to release histamine. 21 In man, there is no evidence of significant cardiovascular activitY,22,23 although one study showed slight slowing of the pulse. 24 Atracurium is also relatively free of muscarinic or ganglionic blocking action and of sympathomimetic effect l9 but there is evidence of histamine release, especially with doses greater than 600 /Ag/kg. Though this appears to be less than that caused by d-tubocurarine or metocurine, it can result in tachycardia or decrease in blood pressure. 25 Most clinical papers report great cardiovascular stability when smaller doses are used. 26 . 27 ,28
Central nervous system effects
Although none of the metabolites of either drug appears to be active on the cardiovascular system, laudanosine, a metabolite of atracurium, is a known CNS stimulant, but does not appear to accumulate to clinically significant concentrations although alteration to the MAC of inhalational agents has been demonstrated in rabbits 29 and EEG changes compatible with arousal have been shown in dogs. 30 Concern about the possibility of toxic levels of laudanosine d~veloping in patients with renal failure has been expressed 31 and in one such patient treated with atracurium by infusion, status epilepticus has been reported. 32 The laudanosine level, however, was a small fraction of that reported to cause seizures in animals 33 ,34 and the fits were ascribed to other causes.
Histamine release and allergic responses
The subject of histamine release by atracurium has received considerable attention. In relation to its blocking potency, its ability to release histamine is less than one-third that of d-tubocurarine. 21 Clinically significant adverse responses, including bronchospasm, hypotension, tachycardia and angioneurotic oedema, have also been reported. [35] [36] [37] [38] [39] In Britain, it is less frequently associated with reports of adverse effects than suxamethonium or alcuronium, but more frequently than d-tubocurarine, pancuronium or vecuronium. 39 This apparent paradox must reflect usage and reporting rate as well as the true frequency of reactions. Slow injection over 75 seconds can prevent increase in plasma histamine following 600 /Ag/kg as well as changes in blood pressure and heart rate. Circulatory effects can also be prevented by pretreatment with HI and H2 antagonists. 40 Vecuronium has little tendency to cause histamine release and wheal formation requires more than eight times the concentration required for atracurium. 41 There are, however, reports of both histaminoid and allergic responses in the literature. 42 -44 Both drugs have the potential to cross react in patients who have documented allergies to other relaxants. 41 ,45
FATE IN THE BODY
Atracurium has two breakdown paths. The first is Hofmann elimination which involves breakage of the link between the quaternary nitrogen and the carbonyl-containing central chain. This breaks the drug down to laudanosine and a quaternary methacrylate. The alternative pathway is the hydrolysis at the ester carbonyl group, yielding a quaternary alcohol and a quaternary acid. 46 Although in high concentrations the breakdown products may be pharmacologically active, there is no evidence of significant action in man. 47 The importance of enzymatic hydrolysis has been debated in the literature. Because the breakdown of atracurium in plasma cholinesterase-deficient patients proceeded normally, it was suggested that enzymatic breakdown was unimportant. 48 It has since been shown that enzymatic hydrolysis in human plasma proceeds at two to three times the rate as in buffer of similar pH. 49 In vivo, in rats, the duration of action of atracurium was prolonged by inhibition of carboxylesterase. 50 Later work, by the same team, using human plasma failed to confirm this,51 but this study was seriously flawed by a poor bioassay technique and the use of concentrations of atracurium several orders of magnitude greater than that which would be encountered in vivo. Such high concentrations would be likely to result in inhibition of esterases or saturation of enzymatic processesY As yet unpublished work in the writer's department has confirmed the findings of Stiller 49 and has shown different breakdown rates for atracurium isomers in human plasma. On balance, it is probable that enzymatic hydrolysis is at least as important a pathway as Hofmann degradation.
The metabolism of vecuronium is more along 'orthodox' lines. Less than 25070 of an injected dose of vecuronium appears in the urine. The main organ of excretion appears to be the liver, with about 20% of the original drug excreted unchanged in bile. The remainder is deacetylated to the 3 and 17 hydroxy and 3,17 dihydroxy compounds. 53 ,54 The 3-0H compound has significant neuromuscular blocking activity, but the concentrations in the plasma were undetectable. Therefore this metabolite is not thought to contribute significantly to pharmacological activity. 20
PHARMACOKINETICS
The usual two or three compartment models with elimination only from the central compartment is probably not applicable to atracurium because Hofmann degradation takes place in the peripheral compartment(s) as well as in the central. Weatherley, Williams and Neill 55 used therefore a modified model to determine that the elimination half life was 20 minutes, the central volume 49.3 mllkg and the clearance 5.1 ml/kg/min. The kinetics of atracurium are little changed by renal failure 56 or liver disease.
In contrast, vecuronium, metabolised principally in the liver or excreted by liver and kidney, fits the orthodox two-or threecompartment kinetic models. Its elimination half-life is considerably longer than that of atracurium, at about 70 to 90 minutes, initial volume of distribution is (V I) 51 mllkg, steadystate volume of distribution (V ss) 252 mllkg and clearance 58 of 4.93 mllkg/min. Renal failure increased the elimination half-life (97 to 150 min) but this was not accompanied by significant difference in the duration of action between the renal failure and control group. Liver disease also increased the half-life significantly, from 58 minutes in the controls to 84 minutes. 59 The volume of distribution in the Anaesthesia and Inlensil'e Cure, Vol. 15. No. /, February, 1987 two groups was similar, but clearance was reduced from 4.26 to 2.73 mllkg/min in the cirrhotics.
It is a puzzling fact that the duration of action of the two drugs under consideration is nearly identical 16 ,60,61 while there is such difference in their elimination half-lives. Effect compartment models can offer a possible explanation.
FACTORS WHICH AFFECT RESPONSE TO ATRACURIUIM AND VECURONIUM

Anaesthetic agents
Anaesthetic agents influence the response to atracurium and vecuronium. Nitrous oxide, narcotics and intravenous induction agents appear to have little effect, but the potent inhalation agents all potentiate these drugs signi ficantly. In general halothane potentiates neuromuscular blockers less than does enflurane or isoflurane and atracurium and vecuronium are less subject to potentiation than pancuronium and d-tubocurarine. 9 Isoflurane 0.75070 (end tidal) reduced the EDso of atracurium from 83 to 68 JAg/kg. 62 In another study, 0.8% halothane (end tidal) increased the mean block following 150 JAg/kg atracurium from 66 to 85 %. 63 The EDso of vecuronium is also reduced in a dose-dependent manner by these volatile agents, halothane being the least and enflurane the most potent. 64 Halothane 0.25 MAC inhaled) reduced the EDso to 77% of control, isoflurane to 53% and enflurane to 35%.65
Suxamethonium
Suxamethonium was found to potentiate the effects of vecuronium administered up to 30 minutes 66 . 67 later. Using smaller doses of both suxamethonium and vecuronium during halothane anaesthesia, however, other workers have failed to confirm this potentiation. 68 Vecuronium has been reported effective in reducing suxamethonium-induced fasciculations and myalgia. Using nitrous oxide-narcotic anaesthesia, potentiation after suxamethonium was also observed with atracurium. 63 Atracurium has been variously reported effective and ineffective in obtunding suxamethonium-induced fasciculations and myalgia 70 ,71 while vecuronium has been reported effective. 72 
Intubation
Neither drug can match suxamethonium for rapid onset of good intubating conditions. Atracurium appears to take about twice as long (198 versus 77 seconds and 150 versus 60 seconds) as suxamethonium to provide good intubating conditions. 8o ,81 Using vecuronium 100 to 200 /..lg/kg, Mirakhur et al. reported good conditions in 58 of 60 patients after 90 seconds. Others reported good conditions after 2 and 2.6 minutes with 100 and 72 /..lg/kg respectively. 82-84 Increasing the dose from 140 to 280 /..lg/kg did not speed up or improve intubating conditions. 85
Cardiac disease and cardiac surgery
Because of the absence of effects on heart rate or blood pressure, vecuronium appears to be the relaxant of choice in patients with heart disease. 86 Unlike pancuronium, vecuronium does not antagonise fentanyl-induced bradycardia 87 and cardiopulmonary bypass under hypothermia prolongs the action of vecuronium. 5 Although in general atracurium has little circulatory effects, occasional hypotension probably due to histamine release may be encountered. 88 
Renal disease
The effects of severe renal disease on the pharmacokinetics of the two drugs have already been discussed. It appears that both drugs are safe to use in such patients and neither prolonged block nor re-curarisation has been reported as yet.
Liver disease
The pharmacokinetics of atracurium did not differ from normal patients in six patients with acute liver and kidney failure. 89 Hunter et al.,  comparing the effects of various doses of vecuronium in cirrhotic patients, found the duration of action of a single 100 /..lg/kg dose shorter than in healthy controls. The action of 200 /..lg/kg, however, was prolonged. They postulate that the termination of action of the smaller dose is by redistribution, possibly into an increased volume, while the prolongation of the larger dose reflects impaired metabolism or excretion. 90
Obstetric anaesthesia
In caesarean sections the ratio of vecuronium in the maternal blood to that in the umbilical cord venous blood was of the order of 9 to 1. 91 Similarly, little atracurium appears to cross the placental barrier 92 and both drugs appear safe for use in obstetric anaesthesia.
Anaesthesia for ophthalmic and neurosurgery
Neither drug raises intraocular pressure 93 ,94 and atracurium has no effect on intracranial pressure even in the presence of tumours. 95 The writer could find no references to the effect of vecuronium on intracranial pressure.
Intercurrent disease states
Atracurium has been reported to have been used successfully in patients with phaeochromocytoma, dystrophic myotonica, myasthenia gravis, Huntington's chorea and malignant hyperthermia syndrome. 96 -IOO Vecuronium in reduced dosage has been used in myasthenia gravis and has been reported safe in pigs liable to malignant hyperthermia. 101,102
Outpatient surgery
Both drugs have been successfully used in anaesthesia for outpatient surgery. Atracurium 250 /..lg/kg with enflurane anaesthesia was used in 26 patients. Patients whose operation lasted Anaesthesia and Intensive Care, Vol. 15, No. I, February, 1987 less than 30 minutes generally required reversal. 103 In another group of 20 outpatients who underwent operations lasting an average of 40 minutes, given vecuronium 45 JAg/kg, nine required reversal at the end of the procedure. 104 
Reversal of neuromuscular block
To date no difficulties with reversal of neuromuscular block have been reported with either drug, albeit in the outpatient study quoted above,103 following atracurium 250 JAg/kg, reversal was sometimes slow if the procedure lasted less than 20 minutes, and in the vecuronium studyl°4 three of the nine patients given edrophonium required two doses. The dose of neostigmine required to antagonise vecuronium blockade is similar to that required for pancuronium, and edrophonium has also been used to reverse vecuronium. 5 . 105 Similarly, both these anticholinesterases are effective in reversing atracurium block. 8 . 106 CONCLUSION To gain experience with these two new drugs, the author has used them extensively in his practice in the last six months. No problems have been experienced, but of course, none would be expected in such a limited number of patients. Cardiovascular stability is impressive with both drugs, and using conservative doses of atracurium (300-400 JAg/kg) injected over 30 seconds, no clinically significant changes in pulse rate (which was monitored by ECG in all patients) were seen, nor were any episodes of hypotension noted in patients with invasive blood pressure monitoring or those in whom blood pressure was automatically recorded at one minute intervals which is the writer's practice during induction. Recovery of neuromuscular function is certainly more rapid than that to which one has been accustomed, and a nerve stimulator for monitoring block is most helpful. For long cases, either intermittent bolus doses or loading doses followed by infusion can be used with prompt recovery or reversal at the end. If the neuromuscular block is quantitatively monitored by transducer or electromyogram, there probably is no need to administer reversing drugs if the train of four ratio is greater than 0.7. If no such monitor is used, it is probably best to adopt a conservative policy of reversal if in any doubt as to the AnaeSlhesia and Intensive Care. Vol. 15 . No. /, P'ehnwry, /987 ability of the patient to sustain muscular contraction.
While there certainly will be an additional monetary cost to the use of these newer drugs, there is no doubt that lack of cardiovascular effects, independence from renal excretion and shorter duration of action make them a significant addition to the anaesthetist's pharmacopoea. Nonetheless it is interesting to note Feldman's comment that the advent of these new and definitely superior relaxants has had no noticeable overall impact on the choice of relaxant in the United Kingdom. 107 
